a public good project by the
Synthesis
Company
of California

© 2026

Martin R. Jefson | doi.page

0 works0 citations0 h-index

Martin R. Jefson

Io Therapeutics (United States)(US)Elusys Therapeutics (United States)(US)

Publications by Year

Research Areas

Antibiotics Pharmacokinetics and Efficacy, Microbial Natural Products and Biosynthesis, Cancer therapeutics and mechanisms, Neuroscience and Neuropharmacology Research, Antibiotic Resistance in Bacteria

Most-Cited Works

→ Quantitative Structure−Activity Relationships among Macrolide Antibacterial Agents: In Vitro and in Vivo Potency against Pasteurella multocida(1997)155 cited
→ Kinetic and structural insights into the binding of histone deacetylase 1 and 2 (HDAC1, 2) inhibitors(2016)74 cited
→ Synthesis and structure-activity relationships of 7-diazabicycloalkylquinolones, including danofloxacin, a new quinolone antibacterial agent for veterinary medicine(1992)47 cited
→ Chemical defense of a rove beetle (Creophilus maxillosus)(1983)42 cited
→ N,N-diethylbenzeneselenamide: a useful reagent for the direct selenenylation of aldehydes(1981)30 cited
→ Novel 1-8-bridged chiral quinolones with activity against topoisomerase II: stereospecificity of the eukaryotic enzyme(1993)16 cited

→ A Phase 1 Single-Ascending-Dose Trial in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravenous PNT001, a Novel Mid-domain Tau Antibody Targeting cis-pT231 Tau(2024)

14 cited

→ UK-69,753, a novel member of the efrotomycin family of antibiotics. II. Structure determination and biological activity.(1989)11 cited

→ Repromicin Derivatives with Potent Antibacterial Activity against Pasteurella multocida(1997)11 cited

→ UK-69,753, a novel member of the efrotomycin family of antibiotics. I. Taxonomy of the producing organism, fermentation and isolation.(1989)7 cited